nodes	percent_of_prediction	percent_of_DWPC	metapath
Apraclonidine—Clonidine—CYP1A1—lung cancer	0.00158	0.653	CrCbGaD
Apraclonidine—Musculoskeletal discomfort—Gemcitabine—lung cancer	0.000882	0.001	CcSEcCtD
Apraclonidine—Dermatitis—Erlotinib—lung cancer	0.000878	0.000995	CcSEcCtD
Apraclonidine—Palpitations—Paclitaxel—lung cancer	0.000878	0.000995	CcSEcCtD
Apraclonidine—Angiopathy—Docetaxel—lung cancer	0.000878	0.000995	CcSEcCtD
Apraclonidine—Skin disorder—Cisplatin—lung cancer	0.000877	0.000994	CcSEcCtD
Apraclonidine—Insomnia—Gemcitabine—lung cancer	0.000876	0.000993	CcSEcCtD
Apraclonidine—Headache—Erlotinib—lung cancer	0.000873	0.00099	CcSEcCtD
Apraclonidine—Mediastinal disorder—Docetaxel—lung cancer	0.000872	0.000988	CcSEcCtD
Apraclonidine—Asthma—Methotrexate—lung cancer	0.000871	0.000987	CcSEcCtD
Apraclonidine—Paraesthesia—Gemcitabine—lung cancer	0.00087	0.000985	CcSEcCtD
Apraclonidine—Asthenia—Vinorelbine—lung cancer	0.000865	0.00098	CcSEcCtD
Apraclonidine—Arrhythmia—Docetaxel—lung cancer	0.000864	0.000979	CcSEcCtD
Apraclonidine—Dyspnoea—Gemcitabine—lung cancer	0.000863	0.000978	CcSEcCtD
Apraclonidine—Chest pain—Etoposide—lung cancer	0.000863	0.000978	CcSEcCtD
Apraclonidine—Nausea—Vinblastine—lung cancer	0.000862	0.000976	CcSEcCtD
Apraclonidine—Somnolence—Gemcitabine—lung cancer	0.000861	0.000976	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Irinotecan—lung cancer	0.000858	0.000973	CcSEcCtD
Apraclonidine—Fatigue—Irinotecan—lung cancer	0.000857	0.000971	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Etoposide—lung cancer	0.000857	0.000971	CcSEcCtD
Apraclonidine—Pruritus—Vinorelbine—lung cancer	0.000853	0.000966	CcSEcCtD
Apraclonidine—Discomfort—Etoposide—lung cancer	0.000852	0.000966	CcSEcCtD
Apraclonidine—Pain—Irinotecan—lung cancer	0.00085	0.000963	CcSEcCtD
Apraclonidine—Constipation—Irinotecan—lung cancer	0.00085	0.000963	CcSEcCtD
Apraclonidine—Mental disorder—Docetaxel—lung cancer	0.000847	0.00096	CcSEcCtD
Apraclonidine—Myalgia—Paclitaxel—lung cancer	0.000846	0.000958	CcSEcCtD
Apraclonidine—Chest pain—Paclitaxel—lung cancer	0.000846	0.000958	CcSEcCtD
Apraclonidine—Face oedema—Doxorubicin—lung cancer	0.000842	0.000955	CcSEcCtD
Apraclonidine—Erythema—Docetaxel—lung cancer	0.000842	0.000954	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—lung cancer	0.00084	0.000952	CcSEcCtD
Apraclonidine—Clonidine—ABCB1—lung cancer	0.000839	0.347	CrCbGaD
Apraclonidine—Nausea—Topotecan—lung cancer	0.000837	0.000949	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Gemcitabine—lung cancer	0.000836	0.000947	CcSEcCtD
Apraclonidine—Discomfort—Paclitaxel—lung cancer	0.000836	0.000947	CcSEcCtD
Apraclonidine—Abdominal discomfort—Methotrexate—lung cancer	0.000835	0.000946	CcSEcCtD
Apraclonidine—Fatigue—Gemcitabine—lung cancer	0.000835	0.000946	CcSEcCtD
Apraclonidine—Pain—Gemcitabine—lung cancer	0.000828	0.000938	CcSEcCtD
Apraclonidine—Constipation—Gemcitabine—lung cancer	0.000828	0.000938	CcSEcCtD
Apraclonidine—Nausea—Erlotinib—lung cancer	0.000828	0.000938	CcSEcCtD
Apraclonidine—Dry mouth—Paclitaxel—lung cancer	0.000827	0.000937	CcSEcCtD
Apraclonidine—Diarrhoea—Vinorelbine—lung cancer	0.000825	0.000935	CcSEcCtD
Apraclonidine—Dysgeusia—Docetaxel—lung cancer	0.000825	0.000934	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Cisplatin—lung cancer	0.000822	0.000932	CcSEcCtD
Apraclonidine—Infection—Etoposide—lung cancer	0.000821	0.000931	CcSEcCtD
Apraclonidine—Feeling abnormal—Irinotecan—lung cancer	0.000819	0.000928	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Irinotecan—lung cancer	0.000813	0.000921	CcSEcCtD
Apraclonidine—Oedema—Paclitaxel—lung cancer	0.000811	0.000919	CcSEcCtD
Apraclonidine—Paraesthesia—Cisplatin—lung cancer	0.00081	0.000919	CcSEcCtD
Apraclonidine—Infection—Paclitaxel—lung cancer	0.000805	0.000913	CcSEcCtD
Apraclonidine—Dyspnoea—Cisplatin—lung cancer	0.000805	0.000912	CcSEcCtD
Apraclonidine—Skin disorder—Etoposide—lung cancer	0.000803	0.00091	CcSEcCtD
Apraclonidine—Feeling abnormal—Gemcitabine—lung cancer	0.000798	0.000904	CcSEcCtD
Apraclonidine—Dizziness—Vinorelbine—lung cancer	0.000797	0.000903	CcSEcCtD
Apraclonidine—Nervous system disorder—Paclitaxel—lung cancer	0.000795	0.000901	CcSEcCtD
Apraclonidine—Skin disorder—Paclitaxel—lung cancer	0.000787	0.000892	CcSEcCtD
Apraclonidine—Abdominal pain—Irinotecan—lung cancer	0.000786	0.000891	CcSEcCtD
Apraclonidine—Nasopharyngitis—Doxorubicin—lung cancer	0.00078	0.000884	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Cisplatin—lung cancer	0.000779	0.000883	CcSEcCtD
Apraclonidine—Infestation NOS—Methotrexate—lung cancer	0.000777	0.00088	CcSEcCtD
Apraclonidine—Infestation—Methotrexate—lung cancer	0.000777	0.00088	CcSEcCtD
Apraclonidine—Pain—Cisplatin—lung cancer	0.000772	0.000875	CcSEcCtD
Apraclonidine—Vomiting—Vinorelbine—lung cancer	0.000766	0.000869	CcSEcCtD
Apraclonidine—Dermatitis—Vinorelbine—lung cancer	0.000759	0.000861	CcSEcCtD
Apraclonidine—Headache—Vinorelbine—lung cancer	0.000755	0.000856	CcSEcCtD
Apraclonidine—Syncope—Docetaxel—lung cancer	0.000755	0.000856	CcSEcCtD
Apraclonidine—Conjunctivitis—Methotrexate—lung cancer	0.000755	0.000855	CcSEcCtD
Apraclonidine—Asthma—Doxorubicin—lung cancer	0.000754	0.000855	CcSEcCtD
Apraclonidine—Palpitations—Docetaxel—lung cancer	0.000744	0.000843	CcSEcCtD
Apraclonidine—Feeling abnormal—Cisplatin—lung cancer	0.000744	0.000843	CcSEcCtD
Apraclonidine—Paraesthesia—Etoposide—lung cancer	0.000742	0.000841	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Paclitaxel—lung cancer	0.000739	0.000837	CcSEcCtD
Apraclonidine—Dyspnoea—Etoposide—lung cancer	0.000737	0.000835	CcSEcCtD
Apraclonidine—Somnolence—Etoposide—lung cancer	0.000735	0.000833	CcSEcCtD
Apraclonidine—Insomnia—Paclitaxel—lung cancer	0.000733	0.000831	CcSEcCtD
Apraclonidine—Hypersensitivity—Irinotecan—lung cancer	0.000732	0.00083	CcSEcCtD
Apraclonidine—Paraesthesia—Paclitaxel—lung cancer	0.000728	0.000825	CcSEcCtD
Apraclonidine—Dyspnoea—Paclitaxel—lung cancer	0.000723	0.000819	CcSEcCtD
Apraclonidine—Somnolence—Paclitaxel—lung cancer	0.000721	0.000817	CcSEcCtD
Apraclonidine—Chest pain—Docetaxel—lung cancer	0.000717	0.000812	CcSEcCtD
Apraclonidine—Myalgia—Docetaxel—lung cancer	0.000717	0.000812	CcSEcCtD
Apraclonidine—Nausea—Vinorelbine—lung cancer	0.000716	0.000811	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Etoposide—lung cancer	0.000714	0.000809	CcSEcCtD
Apraclonidine—Asthenia—Irinotecan—lung cancer	0.000713	0.000808	CcSEcCtD
Apraclonidine—Fatigue—Etoposide—lung cancer	0.000713	0.000808	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—lung cancer	0.000712	0.000807	CcSEcCtD
Apraclonidine—Pain—Etoposide—lung cancer	0.000707	0.000801	CcSEcCtD
Apraclonidine—Constipation—Etoposide—lung cancer	0.000707	0.000801	CcSEcCtD
Apraclonidine—Dry mouth—Docetaxel—lung cancer	0.000701	0.000795	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Paclitaxel—lung cancer	0.0007	0.000793	CcSEcCtD
Apraclonidine—Fatigue—Paclitaxel—lung cancer	0.000699	0.000792	CcSEcCtD
Apraclonidine—Haemorrhage—Methotrexate—lung cancer	0.000697	0.00079	CcSEcCtD
Apraclonidine—Asthenia—Gemcitabine—lung cancer	0.000695	0.000787	CcSEcCtD
Apraclonidine—Constipation—Paclitaxel—lung cancer	0.000693	0.000786	CcSEcCtD
Apraclonidine—Pain—Paclitaxel—lung cancer	0.000693	0.000786	CcSEcCtD
Apraclonidine—Pharyngitis—Methotrexate—lung cancer	0.000692	0.000784	CcSEcCtD
Apraclonidine—Oedema—Docetaxel—lung cancer	0.000687	0.000779	CcSEcCtD
Apraclonidine—Pruritus—Gemcitabine—lung cancer	0.000685	0.000776	CcSEcCtD
Apraclonidine—Infection—Docetaxel—lung cancer	0.000683	0.000774	CcSEcCtD
Apraclonidine—Feeling abnormal—Etoposide—lung cancer	0.000681	0.000772	CcSEcCtD
Apraclonidine—Diarrhoea—Irinotecan—lung cancer	0.00068	0.000771	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Etoposide—lung cancer	0.000676	0.000766	CcSEcCtD
Apraclonidine—Nervous system disorder—Docetaxel—lung cancer	0.000674	0.000764	CcSEcCtD
Apraclonidine—Infestation NOS—Doxorubicin—lung cancer	0.000672	0.000762	CcSEcCtD
Apraclonidine—Infestation—Doxorubicin—lung cancer	0.000672	0.000762	CcSEcCtD
Apraclonidine—Visual impairment—Methotrexate—lung cancer	0.000672	0.000761	CcSEcCtD
Apraclonidine—Feeling abnormal—Paclitaxel—lung cancer	0.000668	0.000757	CcSEcCtD
Apraclonidine—Skin disorder—Docetaxel—lung cancer	0.000667	0.000756	CcSEcCtD
Apraclonidine—Hypersensitivity—Cisplatin—lung cancer	0.000665	0.000754	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Paclitaxel—lung cancer	0.000663	0.000751	CcSEcCtD
Apraclonidine—Diarrhoea—Gemcitabine—lung cancer	0.000663	0.000751	CcSEcCtD
Apraclonidine—Dizziness—Irinotecan—lung cancer	0.000657	0.000745	CcSEcCtD
Apraclonidine—Abdominal pain—Etoposide—lung cancer	0.000654	0.000741	CcSEcCtD
Apraclonidine—Conjunctivitis—Doxorubicin—lung cancer	0.000654	0.000741	CcSEcCtD
Apraclonidine—Eye disorder—Methotrexate—lung cancer	0.000651	0.000738	CcSEcCtD
Apraclonidine—Asthenia—Cisplatin—lung cancer	0.000648	0.000734	CcSEcCtD
Apraclonidine—Abdominal pain—Paclitaxel—lung cancer	0.000641	0.000726	CcSEcCtD
Apraclonidine—Angiopathy—Methotrexate—lung cancer	0.000632	0.000717	CcSEcCtD
Apraclonidine—Vomiting—Irinotecan—lung cancer	0.000632	0.000716	CcSEcCtD
Apraclonidine—Mediastinal disorder—Methotrexate—lung cancer	0.000628	0.000712	CcSEcCtD
Apraclonidine—Dermatitis—Irinotecan—lung cancer	0.000626	0.00071	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Docetaxel—lung cancer	0.000626	0.00071	CcSEcCtD
Apraclonidine—Headache—Irinotecan—lung cancer	0.000623	0.000706	CcSEcCtD
Apraclonidine—Insomnia—Docetaxel—lung cancer	0.000622	0.000704	CcSEcCtD
Apraclonidine—Diarrhoea—Cisplatin—lung cancer	0.000618	0.0007	CcSEcCtD
Apraclonidine—Paraesthesia—Docetaxel—lung cancer	0.000617	0.000699	CcSEcCtD
Apraclonidine—Vomiting—Gemcitabine—lung cancer	0.000616	0.000698	CcSEcCtD
Apraclonidine—Bradycardia—Doxorubicin—lung cancer	0.000615	0.000696	CcSEcCtD
Apraclonidine—Dyspnoea—Docetaxel—lung cancer	0.000613	0.000694	CcSEcCtD
Apraclonidine—Somnolence—Docetaxel—lung cancer	0.000611	0.000692	CcSEcCtD
Apraclonidine—Mental disorder—Methotrexate—lung cancer	0.000611	0.000692	CcSEcCtD
Apraclonidine—Dermatitis—Gemcitabine—lung cancer	0.00061	0.000691	CcSEcCtD
Apraclonidine—Hypersensitivity—Etoposide—lung cancer	0.000609	0.00069	CcSEcCtD
Apraclonidine—Erythema—Methotrexate—lung cancer	0.000607	0.000688	CcSEcCtD
Apraclonidine—Headache—Gemcitabine—lung cancer	0.000607	0.000688	CcSEcCtD
Apraclonidine—Rhinitis—Doxorubicin—lung cancer	0.000605	0.000686	CcSEcCtD
Apraclonidine—Haemorrhage—Doxorubicin—lung cancer	0.000604	0.000684	CcSEcCtD
Apraclonidine—Pharyngitis—Doxorubicin—lung cancer	0.000599	0.000679	CcSEcCtD
Apraclonidine—Hypersensitivity—Paclitaxel—lung cancer	0.000597	0.000677	CcSEcCtD
Apraclonidine—Oedema peripheral—Doxorubicin—lung cancer	0.000595	0.000674	CcSEcCtD
Apraclonidine—Dysgeusia—Methotrexate—lung cancer	0.000594	0.000674	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Docetaxel—lung cancer	0.000593	0.000672	CcSEcCtD
Apraclonidine—Asthenia—Etoposide—lung cancer	0.000593	0.000672	CcSEcCtD
Apraclonidine—Fatigue—Docetaxel—lung cancer	0.000592	0.000671	CcSEcCtD
Apraclonidine—Nausea—Irinotecan—lung cancer	0.00059	0.000669	CcSEcCtD
Apraclonidine—Pain—Docetaxel—lung cancer	0.000588	0.000666	CcSEcCtD
Apraclonidine—Constipation—Docetaxel—lung cancer	0.000588	0.000666	CcSEcCtD
Apraclonidine—Pruritus—Etoposide—lung cancer	0.000585	0.000663	CcSEcCtD
Apraclonidine—Visual impairment—Doxorubicin—lung cancer	0.000582	0.000659	CcSEcCtD
Apraclonidine—Asthenia—Paclitaxel—lung cancer	0.000582	0.000659	CcSEcCtD
Apraclonidine—Nausea—Gemcitabine—lung cancer	0.000575	0.000652	CcSEcCtD
Apraclonidine—Vomiting—Cisplatin—lung cancer	0.000574	0.00065	CcSEcCtD
Apraclonidine—Pruritus—Paclitaxel—lung cancer	0.000574	0.00065	CcSEcCtD
Apraclonidine—Vision blurred—Methotrexate—lung cancer	0.000572	0.000648	CcSEcCtD
Apraclonidine—Dermatitis—Cisplatin—lung cancer	0.000569	0.000644	CcSEcCtD
Apraclonidine—Feeling abnormal—Docetaxel—lung cancer	0.000566	0.000642	CcSEcCtD
Apraclonidine—Diarrhoea—Etoposide—lung cancer	0.000566	0.000641	CcSEcCtD
Apraclonidine—Eye disorder—Doxorubicin—lung cancer	0.000564	0.000639	CcSEcCtD
Apraclonidine—Ill-defined disorder—Methotrexate—lung cancer	0.000563	0.000638	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Docetaxel—lung cancer	0.000562	0.000637	CcSEcCtD
Apraclonidine—Diarrhoea—Paclitaxel—lung cancer	0.000555	0.000629	CcSEcCtD
Apraclonidine—Angiopathy—Doxorubicin—lung cancer	0.000548	0.000621	CcSEcCtD
Apraclonidine—Malaise—Methotrexate—lung cancer	0.000547	0.00062	CcSEcCtD
Apraclonidine—Dizziness—Etoposide—lung cancer	0.000547	0.00062	CcSEcCtD
Apraclonidine—Mediastinal disorder—Doxorubicin—lung cancer	0.000544	0.000617	CcSEcCtD
Apraclonidine—Abdominal pain—Docetaxel—lung cancer	0.000543	0.000616	CcSEcCtD
Apraclonidine—Arrhythmia—Doxorubicin—lung cancer	0.000539	0.000611	CcSEcCtD
Apraclonidine—Dizziness—Paclitaxel—lung cancer	0.000536	0.000608	CcSEcCtD
Apraclonidine—Nausea—Cisplatin—lung cancer	0.000536	0.000608	CcSEcCtD
Apraclonidine—Mental disorder—Doxorubicin—lung cancer	0.000529	0.000599	CcSEcCtD
Apraclonidine—Vomiting—Etoposide—lung cancer	0.000526	0.000596	CcSEcCtD
Apraclonidine—Erythema—Doxorubicin—lung cancer	0.000525	0.000596	CcSEcCtD
Apraclonidine—Dermatitis—Etoposide—lung cancer	0.000521	0.00059	CcSEcCtD
Apraclonidine—Headache—Etoposide—lung cancer	0.000518	0.000587	CcSEcCtD
Apraclonidine—Chest pain—Methotrexate—lung cancer	0.000517	0.000586	CcSEcCtD
Apraclonidine—Myalgia—Methotrexate—lung cancer	0.000517	0.000586	CcSEcCtD
Apraclonidine—Tension—Doxorubicin—lung cancer	0.000516	0.000584	CcSEcCtD
Apraclonidine—Vomiting—Paclitaxel—lung cancer	0.000515	0.000584	CcSEcCtD
Apraclonidine—Dysgeusia—Doxorubicin—lung cancer	0.000515	0.000583	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lung cancer	0.000513	0.000582	CcSEcCtD
Apraclonidine—Dermatitis—Paclitaxel—lung cancer	0.000511	0.000579	CcSEcCtD
Apraclonidine—Discomfort—Methotrexate—lung cancer	0.00051	0.000579	CcSEcCtD
Apraclonidine—Nervousness—Doxorubicin—lung cancer	0.00051	0.000578	CcSEcCtD
Apraclonidine—Headache—Paclitaxel—lung cancer	0.000508	0.000576	CcSEcCtD
Apraclonidine—Hypersensitivity—Docetaxel—lung cancer	0.000506	0.000574	CcSEcCtD
Apraclonidine—Vision blurred—Doxorubicin—lung cancer	0.000495	0.000561	CcSEcCtD
Apraclonidine—Asthenia—Docetaxel—lung cancer	0.000493	0.000559	CcSEcCtD
Apraclonidine—Infection—Methotrexate—lung cancer	0.000492	0.000558	CcSEcCtD
Apraclonidine—Nausea—Etoposide—lung cancer	0.000491	0.000557	CcSEcCtD
Apraclonidine—Ill-defined disorder—Doxorubicin—lung cancer	0.000488	0.000553	CcSEcCtD
Apraclonidine—Pruritus—Docetaxel—lung cancer	0.000486	0.000551	CcSEcCtD
Apraclonidine—Nervous system disorder—Methotrexate—lung cancer	0.000486	0.00055	CcSEcCtD
Apraclonidine—Nausea—Paclitaxel—lung cancer	0.000482	0.000546	CcSEcCtD
Apraclonidine—Skin disorder—Methotrexate—lung cancer	0.000481	0.000545	CcSEcCtD
Apraclonidine—Malaise—Doxorubicin—lung cancer	0.000474	0.000537	CcSEcCtD
Apraclonidine—Syncope—Doxorubicin—lung cancer	0.000471	0.000534	CcSEcCtD
Apraclonidine—Diarrhoea—Docetaxel—lung cancer	0.00047	0.000533	CcSEcCtD
Apraclonidine—Palpitations—Doxorubicin—lung cancer	0.000464	0.000526	CcSEcCtD
Apraclonidine—Dizziness—Docetaxel—lung cancer	0.000454	0.000515	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Methotrexate—lung cancer	0.000451	0.000511	CcSEcCtD
Apraclonidine—Insomnia—Methotrexate—lung cancer	0.000448	0.000508	CcSEcCtD
Apraclonidine—Chest pain—Doxorubicin—lung cancer	0.000447	0.000507	CcSEcCtD
Apraclonidine—Myalgia—Doxorubicin—lung cancer	0.000447	0.000507	CcSEcCtD
Apraclonidine—Paraesthesia—Methotrexate—lung cancer	0.000445	0.000504	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—lung cancer	0.000444	0.000504	CcSEcCtD
Apraclonidine—Discomfort—Doxorubicin—lung cancer	0.000442	0.000501	CcSEcCtD
Apraclonidine—Dyspnoea—Methotrexate—lung cancer	0.000442	0.0005	CcSEcCtD
Apraclonidine—Somnolence—Methotrexate—lung cancer	0.00044	0.000499	CcSEcCtD
Apraclonidine—Dry mouth—Doxorubicin—lung cancer	0.000438	0.000496	CcSEcCtD
Apraclonidine—Vomiting—Docetaxel—lung cancer	0.000437	0.000495	CcSEcCtD
Apraclonidine—Dermatitis—Docetaxel—lung cancer	0.000433	0.000491	CcSEcCtD
Apraclonidine—Headache—Docetaxel—lung cancer	0.00043	0.000488	CcSEcCtD
Apraclonidine—Oedema—Doxorubicin—lung cancer	0.000429	0.000486	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Methotrexate—lung cancer	0.000428	0.000485	CcSEcCtD
Apraclonidine—Fatigue—Methotrexate—lung cancer	0.000427	0.000484	CcSEcCtD
Apraclonidine—Infection—Doxorubicin—lung cancer	0.000426	0.000483	CcSEcCtD
Apraclonidine—Pain—Methotrexate—lung cancer	0.000424	0.00048	CcSEcCtD
Apraclonidine—Nervous system disorder—Doxorubicin—lung cancer	0.000421	0.000477	CcSEcCtD
Apraclonidine—Skin disorder—Doxorubicin—lung cancer	0.000417	0.000472	CcSEcCtD
Apraclonidine—Nausea—Docetaxel—lung cancer	0.000408	0.000463	CcSEcCtD
Apraclonidine—Feeling abnormal—Methotrexate—lung cancer	0.000408	0.000463	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Methotrexate—lung cancer	0.000405	0.000459	CcSEcCtD
Apraclonidine—Abdominal pain—Methotrexate—lung cancer	0.000392	0.000444	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Doxorubicin—lung cancer	0.000391	0.000443	CcSEcCtD
Apraclonidine—Insomnia—Doxorubicin—lung cancer	0.000388	0.00044	CcSEcCtD
Apraclonidine—Paraesthesia—Doxorubicin—lung cancer	0.000385	0.000436	CcSEcCtD
Apraclonidine—Dyspnoea—Doxorubicin—lung cancer	0.000382	0.000433	CcSEcCtD
Apraclonidine—Somnolence—Doxorubicin—lung cancer	0.000381	0.000432	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Doxorubicin—lung cancer	0.00037	0.00042	CcSEcCtD
Apraclonidine—Fatigue—Doxorubicin—lung cancer	0.00037	0.000419	CcSEcCtD
Apraclonidine—Pain—Doxorubicin—lung cancer	0.000367	0.000416	CcSEcCtD
Apraclonidine—Constipation—Doxorubicin—lung cancer	0.000367	0.000416	CcSEcCtD
Apraclonidine—Hypersensitivity—Methotrexate—lung cancer	0.000365	0.000414	CcSEcCtD
Apraclonidine—Asthenia—Methotrexate—lung cancer	0.000355	0.000403	CcSEcCtD
Apraclonidine—Feeling abnormal—Doxorubicin—lung cancer	0.000353	0.000401	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Doxorubicin—lung cancer	0.000351	0.000397	CcSEcCtD
Apraclonidine—Pruritus—Methotrexate—lung cancer	0.00035	0.000397	CcSEcCtD
Apraclonidine—Abdominal pain—Doxorubicin—lung cancer	0.000339	0.000384	CcSEcCtD
Apraclonidine—Diarrhoea—Methotrexate—lung cancer	0.000339	0.000384	CcSEcCtD
Apraclonidine—Dizziness—Methotrexate—lung cancer	0.000328	0.000371	CcSEcCtD
Apraclonidine—Hypersensitivity—Doxorubicin—lung cancer	0.000316	0.000358	CcSEcCtD
Apraclonidine—Vomiting—Methotrexate—lung cancer	0.000315	0.000357	CcSEcCtD
Apraclonidine—Dermatitis—Methotrexate—lung cancer	0.000312	0.000354	CcSEcCtD
Apraclonidine—Headache—Methotrexate—lung cancer	0.00031	0.000352	CcSEcCtD
Apraclonidine—Asthenia—Doxorubicin—lung cancer	0.000308	0.000349	CcSEcCtD
Apraclonidine—Pruritus—Doxorubicin—lung cancer	0.000303	0.000344	CcSEcCtD
Apraclonidine—Nausea—Methotrexate—lung cancer	0.000294	0.000333	CcSEcCtD
Apraclonidine—Diarrhoea—Doxorubicin—lung cancer	0.000293	0.000333	CcSEcCtD
Apraclonidine—Dizziness—Doxorubicin—lung cancer	0.000284	0.000321	CcSEcCtD
Apraclonidine—Vomiting—Doxorubicin—lung cancer	0.000273	0.000309	CcSEcCtD
Apraclonidine—Dermatitis—Doxorubicin—lung cancer	0.00027	0.000306	CcSEcCtD
Apraclonidine—Headache—Doxorubicin—lung cancer	0.000269	0.000304	CcSEcCtD
Apraclonidine—Nausea—Doxorubicin—lung cancer	0.000255	0.000289	CcSEcCtD
Apraclonidine—ADRA2C—Signaling Pathways—TERT—lung cancer	3.59e-05	0.000312	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—HES1—lung cancer	3.58e-05	0.000311	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—APOA1—lung cancer	3.55e-05	0.000308	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—AVP—lung cancer	3.52e-05	0.000306	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—KDR—lung cancer	3.52e-05	0.000305	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—RAF1—lung cancer	3.52e-05	0.000305	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—PIK3CB—lung cancer	3.51e-05	0.000305	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—FGFR1—lung cancer	3.49e-05	0.000303	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—IL2—lung cancer	3.47e-05	0.000301	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—POMC—lung cancer	3.45e-05	0.000299	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—HIF1A—lung cancer	3.44e-05	0.000298	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—PIK3CB—lung cancer	3.43e-05	0.000298	CbGpPWpGaD
Apraclonidine—ADRA2C—Hemostasis—AKT1—lung cancer	3.41e-05	0.000296	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—IGF1R—lung cancer	3.39e-05	0.000294	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—PIK3CA—lung cancer	3.39e-05	0.000294	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—CXCL8—lung cancer	3.37e-05	0.000293	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—CREBBP—lung cancer	3.36e-05	0.000291	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—HES1—lung cancer	3.33e-05	0.000289	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—APOA1—lung cancer	3.32e-05	0.000288	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—CXCL8—lung cancer	3.3e-05	0.000286	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—KDR—lung cancer	3.29e-05	0.000285	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—TP53—lung cancer	3.28e-05	0.000284	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—ERBB3—lung cancer	3.28e-05	0.000284	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—RAF1—lung cancer	3.27e-05	0.000283	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—KIT—lung cancer	3.24e-05	0.000281	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—PIK3CG—lung cancer	3.24e-05	0.000281	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—APC—lung cancer	3.24e-05	0.000281	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—NRAS—lung cancer	3.24e-05	0.000281	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—IL2—lung cancer	3.22e-05	0.00028	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—APOA1—lung cancer	3.22e-05	0.000279	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—EGF—lung cancer	3.2e-05	0.000278	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—PIK3CB—lung cancer	3.19e-05	0.000277	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—PIK3CD—lung cancer	3.18e-05	0.000276	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—IL2—lung cancer	3.15e-05	0.000274	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—ALB—lung cancer	3.14e-05	0.000273	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—TERT—lung cancer	3.14e-05	0.000273	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—HRAS—lung cancer	3.13e-05	0.000272	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—MAPK3—lung cancer	3.1e-05	0.000269	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—POMC—lung cancer	3.08e-05	0.000268	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—CXCL8—lung cancer	3.06e-05	0.000266	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—FGFR1—lung cancer	3.05e-05	0.000265	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—BRAF—lung cancer	3.05e-05	0.000264	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—ERBB3—lung cancer	3.04e-05	0.000264	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—KIT—lung cancer	3.03e-05	0.000263	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—PIK3CG—lung cancer	3.03e-05	0.000263	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—APC—lung cancer	3.03e-05	0.000263	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—NRAS—lung cancer	3.03e-05	0.000263	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—IL6R—lung cancer	3.01e-05	0.000261	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CREBBP—lung cancer	3e-05	0.000261	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—HIF1A—lung cancer	3e-05	0.000261	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—EGF—lung cancer	2.99e-05	0.00026	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—EGFR—lung cancer	2.95e-05	0.000256	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—PIK3CG—lung cancer	2.94e-05	0.000255	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—IL2—lung cancer	2.93e-05	0.000254	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—TERT—lung cancer	2.92e-05	0.000253	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—MAPK3—lung cancer	2.9e-05	0.000252	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—APOA1—lung cancer	2.9e-05	0.000252	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—POMC—lung cancer	2.88e-05	0.00025	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—KDR—lung cancer	2.87e-05	0.000249	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—MAP2K1—lung cancer	2.87e-05	0.000249	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—PIK3CD—lung cancer	2.85e-05	0.000247	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—BRAF—lung cancer	2.84e-05	0.000247	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—FGFR1—lung cancer	2.83e-05	0.000246	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR downstream signaling—PIK3CA—lung cancer	2.82e-05	0.000245	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—IL6R—lung cancer	2.81e-05	0.000244	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CREBBP—lung cancer	2.81e-05	0.000244	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—POMC—lung cancer	2.8e-05	0.000243	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—HIF1A—lung cancer	2.79e-05	0.000242	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—KRAS—lung cancer	2.79e-05	0.000242	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—PIK3CB—lung cancer	2.77e-05	0.000241	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—AKT1—lung cancer	2.77e-05	0.00024	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—EGFR—lung cancer	2.76e-05	0.000239	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—PTGS2—lung cancer	2.75e-05	0.000239	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—CREBBP—lung cancer	2.73e-05	0.000237	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—APOA1—lung cancer	2.69e-05	0.000234	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—MAP2K1—lung cancer	2.68e-05	0.000232	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—KDR—lung cancer	2.67e-05	0.000232	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—PIK3CD—lung cancer	2.66e-05	0.000231	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—KIT—lung cancer	2.65e-05	0.00023	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—APC—lung cancer	2.65e-05	0.00023	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—PIK3CG—lung cancer	2.65e-05	0.00023	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—NRAS—lung cancer	2.65e-05	0.00023	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—PIK3CA—lung cancer	2.64e-05	0.000229	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—EGF—lung cancer	2.62e-05	0.000227	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—KRAS—lung cancer	2.61e-05	0.000226	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—PIK3CD—lung cancer	2.58e-05	0.000224	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—PIK3CA—lung cancer	2.56e-05	0.000222	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—MDM2—lung cancer	2.55e-05	0.000221	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—ALB—lung cancer	2.55e-05	0.000221	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—RAF1—lung cancer	2.54e-05	0.000221	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—MAPK3—lung cancer	2.53e-05	0.00022	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—POMC—lung cancer	2.52e-05	0.000219	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—ERBB2—lung cancer	2.52e-05	0.000218	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—BRAF—lung cancer	2.49e-05	0.000216	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—PIK3CB—lung cancer	2.48e-05	0.000215	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—MTOR—lung cancer	2.48e-05	0.000215	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PIK3CG—lung cancer	2.46e-05	0.000213	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—APC—lung cancer	2.46e-05	0.000213	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—KIT—lung cancer	2.46e-05	0.000213	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—NRAS—lung cancer	2.46e-05	0.000213	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—IL6R—lung cancer	2.46e-05	0.000213	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CREBBP—lung cancer	2.45e-05	0.000213	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—EGF—lung cancer	2.43e-05	0.000211	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—EGFR—lung cancer	2.41e-05	0.000209	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—PTEN—lung cancer	2.4e-05	0.000208	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—PIK3CA—lung cancer	2.39e-05	0.000208	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CXCL8—lung cancer	2.39e-05	0.000207	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—MDM2—lung cancer	2.38e-05	0.000207	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—RAF1—lung cancer	2.38e-05	0.000206	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—HRAS—lung cancer	2.37e-05	0.000206	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—MAPK3—lung cancer	2.35e-05	0.000204	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—ERBB2—lung cancer	2.35e-05	0.000204	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—MAP2K1—lung cancer	2.34e-05	0.000203	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—POMC—lung cancer	2.34e-05	0.000203	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—PIK3CD—lung cancer	2.33e-05	0.000202	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—PIK3CB—lung cancer	2.32e-05	0.000201	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—MTOR—lung cancer	2.32e-05	0.000201	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—BRAF—lung cancer	2.31e-05	0.000201	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR downstream signaling—AKT1—lung cancer	2.3e-05	0.0002	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—PIK3CA—lung cancer	2.3e-05	0.0002	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—EP300—lung cancer	2.29e-05	0.000198	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CASP3—lung cancer	2.28e-05	0.000198	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—IL6R—lung cancer	2.28e-05	0.000198	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—IL2—lung cancer	2.28e-05	0.000198	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CREBBP—lung cancer	2.28e-05	0.000198	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—KRAS—lung cancer	2.28e-05	0.000198	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—IL6—lung cancer	2.27e-05	0.000197	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—PIK3CB—lung cancer	2.25e-05	0.000196	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—EGFR—lung cancer	2.24e-05	0.000194	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—PTGS2—lung cancer	2.23e-05	0.000194	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CXCL8—lung cancer	2.23e-05	0.000193	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CCND1—lung cancer	2.22e-05	0.000193	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—JUN—lung cancer	2.22e-05	0.000193	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—HRAS—lung cancer	2.21e-05	0.000192	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—MAP2K1—lung cancer	2.18e-05	0.000189	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PIK3CD—lung cancer	2.16e-05	0.000188	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—MMP9—lung cancer	2.16e-05	0.000187	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—AKT1—lung cancer	2.15e-05	0.000187	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CDKN1A—lung cancer	2.15e-05	0.000187	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—PTEN—lung cancer	2.15e-05	0.000186	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—PIK3CA—lung cancer	2.14e-05	0.000186	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CASP3—lung cancer	2.13e-05	0.000185	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—IL2—lung cancer	2.13e-05	0.000185	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—IL6—lung cancer	2.12e-05	0.000184	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—KRAS—lung cancer	2.12e-05	0.000184	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—AKT1—lung cancer	2.09e-05	0.000182	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—PIK3CA—lung cancer	2.09e-05	0.000182	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—MDM2—lung cancer	2.08e-05	0.000181	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—RAF1—lung cancer	2.08e-05	0.00018	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CCND1—lung cancer	2.08e-05	0.00018	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—JUN—lung cancer	2.07e-05	0.00018	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—ERBB2—lung cancer	2.05e-05	0.000178	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—EP300—lung cancer	2.05e-05	0.000178	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—MTOR—lung cancer	2.03e-05	0.000176	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—PIK3CB—lung cancer	2.03e-05	0.000176	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—MMP9—lung cancer	2.02e-05	0.000175	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CDKN1A—lung cancer	2.01e-05	0.000174	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—PTEN—lung cancer	2e-05	0.000174	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—SRC—lung cancer	1.99e-05	0.000173	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—AKT1—lung cancer	1.96e-05	0.00017	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CXCL8—lung cancer	1.95e-05	0.000169	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—PTEN—lung cancer	1.95e-05	0.000169	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—PIK3CA—lung cancer	1.94e-05	0.000169	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—VEGFA—lung cancer	1.94e-05	0.000168	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—MDM2—lung cancer	1.94e-05	0.000168	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—HRAS—lung cancer	1.94e-05	0.000168	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—RAF1—lung cancer	1.93e-05	0.000167	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—STAT3—lung cancer	1.92e-05	0.000167	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—NRAS—lung cancer	1.91e-05	0.000166	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—EP300—lung cancer	1.91e-05	0.000166	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—ERBB2—lung cancer	1.91e-05	0.000166	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—MTOR—lung cancer	1.88e-05	0.000163	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PIK3CB—lung cancer	1.88e-05	0.000163	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—AKT1—lung cancer	1.88e-05	0.000163	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CASP3—lung cancer	1.86e-05	0.000162	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—IL2—lung cancer	1.86e-05	0.000162	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—SRC—lung cancer	1.86e-05	0.000161	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—EP300—lung cancer	1.86e-05	0.000161	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—IL6—lung cancer	1.85e-05	0.000161	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—MAPK3—lung cancer	1.83e-05	0.000159	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CCND1—lung cancer	1.82e-05	0.000158	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—JUN—lung cancer	1.81e-05	0.000157	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CXCL8—lung cancer	1.81e-05	0.000157	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—VEGFA—lung cancer	1.81e-05	0.000157	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—HRAS—lung cancer	1.8e-05	0.000156	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—STAT3—lung cancer	1.79e-05	0.000156	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—NRAS—lung cancer	1.79e-05	0.000155	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—MYC—lung cancer	1.78e-05	0.000155	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—MMP9—lung cancer	1.76e-05	0.000153	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CDKN1A—lung cancer	1.76e-05	0.000152	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—PTEN—lung cancer	1.75e-05	0.000152	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—AKT1—lung cancer	1.75e-05	0.000152	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—EGFR—lung cancer	1.74e-05	0.000151	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CASP3—lung cancer	1.73e-05	0.00015	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—IL2—lung cancer	1.73e-05	0.00015	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—IL6—lung cancer	1.72e-05	0.000149	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—MAPK3—lung cancer	1.71e-05	0.000149	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—AKT1—lung cancer	1.71e-05	0.000148	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—PIK3CA—lung cancer	1.69e-05	0.000147	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CCND1—lung cancer	1.69e-05	0.000146	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—JUN—lung cancer	1.68e-05	0.000146	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—EP300—lung cancer	1.67e-05	0.000145	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—MYC—lung cancer	1.67e-05	0.000145	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—KRAS—lung cancer	1.65e-05	0.000143	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—MMP9—lung cancer	1.64e-05	0.000142	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CDKN1A—lung cancer	1.63e-05	0.000142	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—EGFR—lung cancer	1.63e-05	0.000141	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PTEN—lung cancer	1.63e-05	0.000141	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—SRC—lung cancer	1.62e-05	0.000141	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—AKT1—lung cancer	1.59e-05	0.000138	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—VEGFA—lung cancer	1.58e-05	0.000137	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—STAT3—lung cancer	1.57e-05	0.000136	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—NRAS—lung cancer	1.56e-05	0.000136	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—EP300—lung cancer	1.55e-05	0.000135	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—KRAS—lung cancer	1.54e-05	0.000134	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—PIK3CA—lung cancer	1.51e-05	0.000131	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—SRC—lung cancer	1.51e-05	0.000131	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—MAPK3—lung cancer	1.5e-05	0.00013	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—VEGFA—lung cancer	1.47e-05	0.000128	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—TP53—lung cancer	1.46e-05	0.000127	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—MYC—lung cancer	1.46e-05	0.000126	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—STAT3—lung cancer	1.46e-05	0.000126	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—NRAS—lung cancer	1.45e-05	0.000126	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—EGFR—lung cancer	1.42e-05	0.000124	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—PIK3CA—lung cancer	1.41e-05	0.000123	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—HRAS—lung cancer	1.4e-05	0.000122	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—MAPK3—lung cancer	1.39e-05	0.000121	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—AKT1—lung cancer	1.38e-05	0.00012	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—PIK3CA—lung cancer	1.37e-05	0.000119	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—TP53—lung cancer	1.37e-05	0.000119	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—MYC—lung cancer	1.35e-05	0.000117	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—KRAS—lung cancer	1.35e-05	0.000117	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—IL6—lung cancer	1.34e-05	0.000116	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—EGFR—lung cancer	1.32e-05	0.000115	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—HRAS—lung cancer	1.31e-05	0.000114	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—IL6—lung cancer	1.25e-05	0.000109	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—KRAS—lung cancer	1.25e-05	0.000108	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—AKT1—lung cancer	1.24e-05	0.000107	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—PIK3CA—lung cancer	1.24e-05	0.000107	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—TP53—lung cancer	1.2e-05	0.000104	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—AKT1—lung cancer	1.15e-05	0.0001	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PIK3CA—lung cancer	1.15e-05	9.97e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—HRAS—lung cancer	1.14e-05	9.92e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—AKT1—lung cancer	1.12e-05	9.74e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—TP53—lung cancer	1.11e-05	9.64e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—IL6—lung cancer	1.09e-05	9.5e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—HRAS—lung cancer	1.06e-05	9.22e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—IL6—lung cancer	1.02e-05	8.83e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—AKT1—lung cancer	1.01e-05	8.76e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—AKT1—lung cancer	9.38e-06	8.14e-05	CbGpPWpGaD
